SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India
Copyright © 2023 Doke, Mhaske, Oka, Kulkarni, Muley, Mishra and Arankalle..
Breakthrough infections following SARS-CoV-2 vaccination remain the global concern. The current study was conducted during the second wave of COVID-19 (1st March-7th July 2021) in Pune, India, at two tertiary care hospitals. Of the 6,159 patients diagnosed as COVID-19, 372/2,210 (16.8%) were breakthrough infections. Of these, 81.1 and 18.8% received one or two doses of Covishield or Covaxin, respectively. Of note, 30.7% patients were with comorbidities, hypertension being the commonest (12.44%). The majority of infections were mild (81.2%). Forty-three patients with breakthrough infections were hospitalized with severe (n = 27, 62.8%) or moderate (n = 16, 37.2%) disease. The receptor binding domain (RBD) sequences from vaccinated (n = 126) and non-vaccinated (n = 168) samples were used for variant analysis. The delta variant was predominant followed by kappa in both vaccinated and non-vaccinated groups. Viral load (qRT-PCR) was not different among these categories. Full-genome comparisons of sequences in relation to vaccination status did not identify any mutation characteristic of the vaccinated group. Irrespective of the number of doses, neutralizing antibody titers (PRNT50) during the first week of clinical disease were higher in the vaccinated patients than the unvaccinated category. In conclusion, though not completely, SARS-CoV-2 vaccines used for country-wide immunization did reduce disease severity among the individuals without any comorbidity by inducing rapid immune response against distinctly different delta and kappa variants. The utility against emerging variants with further mutations need to be carefully examined.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in public health - 10(2022) vom: 21., Seite 1040012 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Doke, Prakash P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.01.2023 Date Revised 03.11.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fpubh.2022.1040012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352217421 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352217421 | ||
| 003 | DE-627 | ||
| 005 | 20231226053220.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fpubh.2022.1040012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352217421 | ||
| 035 | |a (NLM)36711329 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Doke, Prakash P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2023 | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Doke, Mhaske, Oka, Kulkarni, Muley, Mishra and Arankalle. | ||
| 520 | |a Breakthrough infections following SARS-CoV-2 vaccination remain the global concern. The current study was conducted during the second wave of COVID-19 (1st March-7th July 2021) in Pune, India, at two tertiary care hospitals. Of the 6,159 patients diagnosed as COVID-19, 372/2,210 (16.8%) were breakthrough infections. Of these, 81.1 and 18.8% received one or two doses of Covishield or Covaxin, respectively. Of note, 30.7% patients were with comorbidities, hypertension being the commonest (12.44%). The majority of infections were mild (81.2%). Forty-three patients with breakthrough infections were hospitalized with severe (n = 27, 62.8%) or moderate (n = 16, 37.2%) disease. The receptor binding domain (RBD) sequences from vaccinated (n = 126) and non-vaccinated (n = 168) samples were used for variant analysis. The delta variant was predominant followed by kappa in both vaccinated and non-vaccinated groups. Viral load (qRT-PCR) was not different among these categories. Full-genome comparisons of sequences in relation to vaccination status did not identify any mutation characteristic of the vaccinated group. Irrespective of the number of doses, neutralizing antibody titers (PRNT50) during the first week of clinical disease were higher in the vaccinated patients than the unvaccinated category. In conclusion, though not completely, SARS-CoV-2 vaccines used for country-wide immunization did reduce disease severity among the individuals without any comorbidity by inducing rapid immune response against distinctly different delta and kappa variants. The utility against emerging variants with further mutations need to be carefully examined | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a breakthrough infection | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a variants | |
| 650 | 7 | |a BBV152 COVID-19 vaccine |2 NLM | |
| 650 | 7 | |a 76JZE5DSN6 |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 700 | 1 | |a Mhaske, Suhas T |e verfasserin |4 aut | |
| 700 | 1 | |a Oka, Gauri |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Ruta |e verfasserin |4 aut | |
| 700 | 1 | |a Muley, Vrishali |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Akhilesh Chandra |e verfasserin |4 aut | |
| 700 | 1 | |a Arankalle, Vidya A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in public health |d 2013 |g 10(2022) vom: 21., Seite 1040012 |w (DE-627)NLM23377548X |x 2296-2565 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g day:21 |g pages:1040012 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fpubh.2022.1040012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |b 21 |h 1040012 | ||